» Articles » PMID: 12244303

Cytoplasmic Relocalization and Inhibition of the Cyclin-dependent Kinase Inhibitor P27(Kip1) by PKB/Akt-mediated Phosphorylation in Breast Cancer

Overview
Journal Nat Med
Date 2002 Sep 24
PMID 12244303
Citations 230
Authors
Affiliations
Soon will be listed here.
Abstract

The cyclin-dependent kinase inhibitor p27(kip1) is a putative tumor suppressor for human cancer. The mechanism underlying p27(kip1) deregulation in human cancer is, however, poorly understood. We demonstrate that the serine/threonine kinase Akt regulates cell proliferation in breast cancer cells by preventing p27(kip1)-mediated growth arrest. Threonine 157 (T157), which maps within the nuclear localization signal of p27(kip1), is a predicted Akt-phosphorylation site. Akt-induced T157 phosphorylation causes retention of p27(kip1) in the cytoplasm, precluding p27(kip1)-induced G1 arrest. Conversely, the p27(kip1)-T157A mutant accumulates in cell nuclei and Akt does not affect p27(kip1)-T157A-mediated cell cycle arrest. Lastly, T157-phosphorylated p27(kip1) accumulates in the cytoplasm of primary human breast cancer cells coincident with Akt activation. Thus, cytoplasmic relocalization of p27(kip1), secondary to Akt-mediated phosphorylation, is a novel mechanism whereby the growth inhibitory properties of p27(kip1) are functionally inactivated and the proliferation of breast cancer cells is sustained.

Citing Articles

Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis.

Huang Y, Lu H, Liu Y, Wang J, Xia Q, Shi X EMBO J. 2025; 44(5):1414-1441.

PMID: 39875724 PMC: 11876615. DOI: 10.1038/s44318-024-00359-z.


C-terminally phosphorylated p27 activates self-renewal driver genes to program cancer stem cell expansion, mammary hyperplasia and cancer.

Razavipour S, Yoon H, Jang K, Kim M, Nawara H, Bagheri A Nat Commun. 2024; 15(1):5152.

PMID: 38886396 PMC: 11183067. DOI: 10.1038/s41467-024-48742-y.


The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.

Park M, Jung E, Park J, Park S, Ko D, Seo J Theranostics. 2024; 14(6):2442-2463.

PMID: 38646654 PMC: 11024854. DOI: 10.7150/thno.93236.


CIP/KIP and INK4 families as hostages of oncogenic signaling.

Csergeova L, Krbusek D, Janostiak R Cell Div. 2024; 19(1):11.

PMID: 38561743 PMC: 10985988. DOI: 10.1186/s13008-024-00115-z.


The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.

Karatrasoglou E, Dimou M, Piperidou A, Lakiotaki E, Korkolopoulou P, Vassilakopoulos T Int J Mol Sci. 2023; 24(18).

PMID: 37762410 PMC: 10531792. DOI: 10.3390/ijms241814110.